WA-REMOTE-MEDICAL-INTL
15.7.2020 15:02:12 CEST | Business Wire | Press release
Remote Medical International, a global leader in workplace health and safety services for Fortune 100 corporations and government services prime contractors, announced it completed its acquisition of SSI Group on July 1. Based in the United Kingdom, SSI specializes in emergency response medical services for the oil and gas and renewable energy sectors, global risk management, and international safety.
“This acquisition is part of our strategy to aggressively expand into new markets, notably renewable energy, broaden our offerings to include risk management, and build on our leading COVID-19 services,” said Wayne Wager, CEO of Remote Medical International. “The complementary nature of our businesses adds to our ability to design bespoke solutions for our clients that save lives and improve the health of workers in diverse job sites around the world.”
Remote Medical International will leverage SSI’s years of work to provide medical and technical support for offshore wind farm and other renewable energy construction in the North Sea and North America and expand its work with large corporations working in remote and challenging locations globally. The combined expertise will produce a comprehensive range of COVID-19 medical services and solutions for businesses seeking to create safe back-to-work situations under one Remote Medical International offering.
The combined companies will deliver unparalleled quality by setting the highest standards for medical and safety personnel and clinical governance. Customers will benefit from the companies’ vast experience in offering workplace health and safety and risk management services to more than 120 countries across the globe.
“We are delighted to join the Remote Medical International team and believe that together our companies will deliver greater value to our customers through our common values of quality, agility, responsiveness, and collaboration,” said Duncan Higham, Founder and Managing Director of SSI. ”We share a passion for delivering unparalleled services and a vision of being the best remote medical provider on land and at sea.”
Mr. Higham has been named Remote Medical International’s vice president global strategy, reporting directly to Wayne Wager, CEO of Remote Medical International. Julian Rawles, formerly SSI’s commercial director, will serve as the managing director of Remote Medical International UK reporting to Paul Budak, chief operating officer. No other changes in either organization are anticipated. The terms of the acquisition were not disclosed. Visit the company’s website, https://remotemedical.com/ for more information.
About Remote Medical International
Headquartered in Seattle, Washington, Remote Medical International saves lives and protects the health and wellbeing of workers in diverse job sites from remote pipeline installations to offshore wind and maritime operations. The company has been recognized six times by Inc. 5000 as one of the fastest-growing companies in the United States and works with Fortune 100 corporations and government services prime contractors.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200715005453/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTM to Drive AI-Powered Modernization of IT Infrastructure and Application Support for UK-based SSP Group26.5.2026 11:00:00 CEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, has entered a strategic partnership with SSP Group, a leading operator of food and beverage outlets in travel locations worldwide. Through this AI-powered partnership, LTM will deliver modernized, end-to-end IT infrastructure support and enhanced application maintenance services to SSP Group. As part of this engagement, LTM will leverage its advanced AI capabilities including its BlueVerseTM ecosystem to help SSP manage operational risks, simplify infrastructure and application complexities, and drive business efficiency and agility. Additionally, the collaboration will focus on enabling data-driven decision-making, accelerating innovation through automation, delivering scalable solutions that enhance customer experience, and driving cost optimization through AI automation and simplification. “As we continue to advance our IT capabilities, having a trusted partner like LTM with deep domain expertise and a focus on
ROYC and Stilla Enter Strategic Partnership to Operationalise Agentic AI in Private Markets26.5.2026 10:30:00 CEST | Press release
ROYC today announced a partnership with Stilla.ai as the platform layer where ROYC will create, share and run its internally developed AI skills and agents. This operationalises the agentic AI strategy ROYC set out earlier, equipping every function across the company with the tools and resources to build and deploy their own AI agents and converting this into measurable productivity gains and accelerated product development. This will substantially accelerate launch of new platform features, improving cost efficiency at the same time as strengthening overall governance and oversight. For ROYC’s customers and partners, the result will be shorter time-to-market for new product releases, shorter time frames moving from idea to productification and tailored customer experience from an investor services perspective. “Our strategy is clear: AI is embedded in every aspect of our ways of working and what the ROYC Operating System does, not a side project,” said Peter Bergenwald, CTO of ROYC. “
IQOS One of the Most Valuable Global Brands, According to Kantar’s BrandZ 2026 Ranking26.5.2026 10:00:00 CEST | Press release
Recognition reinforces the growing consumer relevance of IQOS and the strength of Philip Morris International’s smoke-free vision Philip Morris International’s (PMI) (NYSE: PM) IQOS, the #1 tobacco heating system1, has been listed for the first time as one of the top 100 most valuable brands in the world in Kantar’s BrandZ 2026 Most Valuable Global Brands. This ranking solidifies IQOS’s global momentum and its emergence as a culturally relevant, iconic brand for adult nicotine users seeking better alternatives to cigarettes. According to the BrandZ 2026 Most Valuable Global Brands, IQOS achieved a ranking of #74 globally. With more than 35 million IQOS users worldwide—most of whom have fully switched away from cigarettes2—the brand continues to lead from the front and champion in a smoke-free era through science-backed innovation and consumer-centric design. Within 10 years of inception, IQOS surpassed $10 billion in annual net revenues, reaching this milestone faster than some of the
Quectel Expands EMEA Reach With Future Electronics Distribution Agreement26.5.2026 10:00:00 CEST | Press release
Quectel Wireless Solutions, a global end-to-end IoT solutions provider, today announced an expanded distribution partnership with Future Electronics to bring its full portfolio of products and services to customers across the EMEA region. Under this agreement, Future Electronics will bring Quectel’s full IoT portfolio to customers across Europe, the Middle East and Africa, with a strong focus on its non-cellular solutions, including antennas, GNSS, Wi-Fi, Bluetooth and smart modules. This collaboration marks a significant step in strengthening Quectel’s presence in EMEA, leveraging Future Electronics’ strong regional infrastructure, technical expertise, and established customer relationships to accelerate growth and innovation. “Future Electronics’ extensive footprint and demand creation capabilities make them an ideal partner for expanding our reach across EMEA,” said Natasha Barrios, Senior Vice President, EMEA, Quectel Wireless Solutions. “By working together, we can ensure faster a
Merz Therapeutics and Kvvit Enter Exclusive Agreement for INBRIJA® (levodopa inhalation powder) in Mainland China, Hong Kong and Macao26.5.2026 09:00:00 CEST | Press release
Kvvit to lead local development, regulatory activities and commercialization of INBRIJA® in mainland China, Hong Kong and Macao Under the agreement, Merz Therapeutics will receive upfront, development and commercial milestone payments, and tiered supply and royalty arrangements, with no manufacturing rights granted to Kvvit Merz Therapeutics GmbH and Jiangxi Kvvit Pharmaceutical Co. Ltd. today announced that the companies have entered into an exclusive license and collaboration agreement regarding INBRIJA® (levodopa inhalation powder) and its proprietary inhalation device for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor in mainland China, Hong Kong and Macao. Under the agreement, Merz will supply INBRIJA® and retain responsibility for global product quality and key regulatory activities. Kvvit will lead development, regulatory activities and commercializat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom